

## Original Research

### Comparison of Bleeding Risks and All-Cause Death Between Warfarin and Direct Oral Anticoagulants in Patients With Atrial Fibrillation and Chronic Obstructive Pulmonary Disease: A Multicenter Retrospective Cohort Study

Na Zhao<sup>1,2\*</sup> Ting Wei<sup>1\*</sup> Xinhai Huang<sup>1</sup> Guilan Wu<sup>1</sup> Ruijuan Li<sup>3</sup> Qiaowei Zheng<sup>4</sup> Xiumei Liu<sup>5</sup> Hengfen Dai<sup>6</sup> Xiangsheng Lin<sup>7</sup> Yuxin Liu<sup>8</sup> Jun Su<sup>9</sup> Xiaomin Dong<sup>10</sup> Cuifang You<sup>11</sup> Shuzheng Jiang<sup>12</sup> Yanxian Lan<sup>13</sup> Jinhua Zhang, PhD<sup>1</sup>

<sup>1</sup> Department of Pharmacy, Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, China

<sup>2</sup> School of Public Health, Fujian Medical University, Fuzhou, China

<sup>3</sup> Shanxi Bethune Hospital, Taiyuan, China

<sup>4</sup> First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

<sup>5</sup> People's Hospital of He'nan University of Chinese Medicine, Zhengzhou, China

<sup>6</sup> Affiliated Fuzhou First Hospital of Fujian Medical University, Fuzhou, China

<sup>7</sup> Pingtan County General Laboratory Area Hospital, Fuzhou, China

<sup>8</sup> Huaihe Hospital of Henan University, Kaifeng, China

<sup>9</sup> Department of Pharmacy, the First Affiliated Hospital of Bengbu Medical College, Bengbu, China

<sup>10</sup> Affiliated Hospital of Guilin Medical University, Guilin, China

<sup>11</sup> Ningde Municipal Hospital Affiliated to Ningde Normal University, Ningde, China

<sup>12</sup> Wuhan Hospital of Traditional Chinese and Western Medicine, Wuhan, China

<sup>13</sup> Minzu Hospital of Guangxi Zhuang Autonomous Region, Nanning, China

\* *contributed to the work equally*

**Address correspondence to:**

Jinhua Zhang, PhD  
Department of Pharmacy  
Fujian Maternity and Child Health Hospital  
College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics  
Fujian Medical University  
#18 Daoshan Road  
Fuzhou, 350001, China  
Phone: 86 591 83357896 8301  
Email: pollyzhang2006@126.com

**Running Head: Bleeding Risks With Warfarin Versus DOACs in COPD-AF**

**Keywords:** atrial fibrillation; chronic obstructive pulmonary disease; direct oral anticoagulants; warfarin; bleeding

**Abbreviations:** AF: atrial fibrillation, AECOPD: acute exacerbation of chronic obstructive pulmonary disease, aOR: adjusted odds ratio, AR: absolute risk, ARB: angiotensin II receptor blocker, ALT: alanine aminotransferase, AST: aspartate aminotransferase, ATO: average treatment effect in the overlap population, BMI: body mass index, CCB: calcium channel blocker, CI: confidence interval, COPD: chronic obstructive pulmonary disease, CRNMB: clinically relevant non-major bleeding, DOACs: direct oral anticoagulants, eGFR: estimated glomerular filtration rate, EMR: electronic medical record, FXa: factor Xa, IQR: interquartile range, ISTH: International Society on Thrombosis and Haemostasis, IPTW: inverse probability of treatment weighting, LMWH: low-molecular-weight heparin, NACE: net adverse clinical events, NNH: number needed to harm, NNT: number needed to treat, NSAIDs: non-steroidal anti-inflammatory drugs, OW: overlap weighting, PE: pulmonary embolism, PPI: proton pump inhibitor, PS: propensity score, PSM: propensity score matching, RD: risk difference, SD: standard deviation, SE: systemic embolism, SMD: standardized mean difference, TBil: total bilirubin, TIA: transient ischemic attack, TTR: time in therapeutic range, VKA: vitamin K antagonist, VTE: venous thromboembolism.

**Funding Support:** Fund for Health Research of Fujian Province (Grant number: 2023-63)

**Date of Acceptance:** February 9, 2026 | **Published Online Date:** February 23, 2026

**Citation:** Zhao N, Wei T, Huang X, et al. Comparison of bleeding risks and all-cause death between warfarin and direct oral anticoagulants in patients with atrial fibrillation and chronic obstructive pulmonary disease: a multicenter retrospective cohort study. *Chronic Obstr Pulm Dis.* 2026; Published online February 23, 2026.

<https://doi.org/10.15326/jcopdf.2025.0648>

*This article has an online supplement.*

Pre-proof

## Abstract

**Background:** Chronic obstructive pulmonary disease (COPD) may influence bleeding in atrial fibrillation (AF). We evaluated bleeding and all-cause death risks under warfarin versus direct oral anticoagulants (DOACs).

**Methods:** Based on retrospective cohort from 12 centers of patients with AF on oral anticoagulation, we evaluated the associations of COPD and anticoagulant class with clinical outcomes using overlap-weighted logistic regression. Prespecified sensitivity and subgroup analyses were performed.

**Results:** COPD was associated with higher bleeding risk only among patients treated with warfarin (total bleeding: OR 2.53, 95% CI 1.00–6.45; RD 9.05%, 95% CI 0.15–22.50%; minor bleeding: aOR 3.00, 95% CI 1.09–8.24; RD 8.53%, 95% CI 0.56–21.53%). Among patients with AF and COPD, DOAC were associated with reduced risks of total bleeding (OR 0.08, 95% CI 0.01–0.50; RD –8.4%, 95% CI –22.0 to –5.3%) and minor bleeding (OR 0.01; RD –9.5%, 95% CI –23.1 to –4.5%) compared with warfarin.

Subgroup analyses suggested that DOAC were associated with increased mortality at eGFR  $\geq 60$  mL/min/1.73 m<sup>2</sup> (OR 3.07, 95% CI 0.78–12.03; RD 9.9%) but lower mortality at eGFR  $< 60$  mL/min/1.73 m<sup>2</sup> (OR 0.20, 95% CI 0.05–0.78; RD –24.1%). FXa inhibitors were associated with higher major bleeding risk compared with dabigatran (OR 4.56, 95% CI 1.70–12.26; RD 10.2%, 95% CI 0.2–20.1%; with a number needed to harm (NNH) of 10.).

**Conclusions:** In AF with comorbid COPD, DOACs minimize bleeding versus warfarin and may

confer survival benefit in renal impairment. Choice among DOACs should consider differential bleeding risk.

Pre-proof

## Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, and its incidence and prevalence have been increasing globally in recent years[1]. Ischemic stroke and thromboembolism in other parts of the body are the main causes of morbidity and mortality in patients with AF[2], with AF increasing the risk of ischemic stroke by three to five times. It is estimated that 15% of strokes worldwide are attributable to AF[3]. To prevent thrombotic events such as ischemic stroke, patients with AF typically receive anticoagulant medications for prophylactic treatment[1,4]. However, anticoagulation inevitably carries the risk of bleeding, with severe bleeding potentially being fatal[5,6]. The incidence of AF increases with age, and therefore, patients often have multiple comorbidities. Apart from cardiovascular and cerebrovascular diseases, Chronic Obstructive Pulmonary Disease (COPD) is a common comorbidity in patients with AF, affecting about 13% of these patients[7,8].

COPD is a heterogeneous lung disease caused by smoking and the inhalation of toxic particles and gases indoors and outdoors, often leading to persistent airflow obstruction and respiratory symptoms[9]. It is characterized by localized inflammation in the lungs to inhaled substances (such as cigarette smoke and air pollutants) and even systemic inflammation[10]. Inflammatory diseases, as risk factors for Venous Thromboembolism (VTE), can induce thrombosis[11]. VTE is the most common and potentially fatal complication in COPD patients hospitalized for exacerbation[12]. Apart from VTE, the incidence of Pulmonary Embolism (PE) in COPD patients should not be overlooked. A population-based cohort study showed that the

incidence of PE in COPD patients is 12.31/10,000 person-years, which is approximately four times higher than in those without COPD[13]. In patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD), there is a significant correlation between blood coagulation and anticoagulation processes as well as between oxidative and antioxidative mechanisms. Early anticoagulation may improve the prognosis of these patients. Using low molecular weight heparin or oral anticoagulation may improve lung function and slow disease progression in patients with AECOPD[14]. Current guidelines and the Global Initiative for Chronic Obstructive Lung Disease support anticoagulation therapy for patients with AECOPD. However, to date, there is no consensus on prophylactic anticoagulation therapy in COPD patients[9].

Due to the high risk of ischemic stroke and other thromboembolic events in patients with AF, those with concurrent COPD must undergo prophylactic anticoagulation therapy. However, COPD is not merely a localized inflammatory disease of the lungs but a systemic inflammatory condition. Owing to persistent airway obstruction and decline in lung function, such patients often experience prolonged hypoxemia, chronic inflammatory responses[9,15], and long-term use of inhaled medications and other treatments. These factors may alter coagulation mechanisms, thereby increasing the risk of bleeding. Pulmonary diseases may lead to hemoptysis or bronchial bleeding, and anticoagulation could exacerbate these conditions, increasing the risk of severe bleeding events. Studies have found that AF patients with COPD have a higher risk of major bleeding compared to those without COPD[16]. Different anticoagulants, especially

warfarin and Direct Oral Anticoagulants (DOACs), vary in their mechanisms of action and metabolic pathways, thus differing in bleeding risks. Therefore, the choice of oral anticoagulants is particularly crucial for AF patients requiring prophylactic treatment when combined with COPD.

In recent years, studies exploring the efficacy and safety of different types of oral anticoagulants in patients with AF and other cardiovascular diseases (such as hypertension, chronic coronary artery disease), chronic kidney disease, and liver dysfunction have been published[17–20]. However, there is a lack of research focused on AF patients with COPD. The risks of bleeding and all-cause death associated with different oral anticoagulants in patients with AF and COPD remain unclear. Therefore, based on real-world data, we conducted a multicenter retrospective cohort study aimed at comparing the risks of bleeding and all-cause death (including major bleeding, minor bleeding, total bleeding, and all-cause death events) between warfarin and DOACs in patients with AF and COPD undergoing anticoagulation.

## **Methods**

### **Study design**

From January 2016 to December 2020, we conducted a retrospective cohort study across 12 centers in China to analyze the risks of bleeding and all-cause death in patients with AF and COPD who were treated with different oral anticoagulants, the list of multicenter hospitals is provided in Supplementary Table 1. The Institutional Review Board of Fujian Maternal and Child Health Hospital approved the protocol (Registration No.: ChiCTR 2300067734). As the

study was retrospective, the Institutional Review Board waived the requirement for patient informed consent. The inclusion criteria for the study were as follows: (1) patients diagnosed with AF; (2) patients currently receiving treatment with warfarin or DOACs (including dabigatran, rivaroxaban, apixaban, and edoxaban); The exclusion criteria were as follows: (1) patients with valvular AF; (2) patients aged  $\leq 18$  years; (3) missing baseline information; (4) loss to follow-up. Ultimately, 11132 patients receiving oral anticoagulant therapy for AF were included in this study, with an average follow-up period of about 13 months. The flowchart of participant inclusion is shown in Figure 1. These patients were divided into two subgroups: patients with AF and concomitant COPD (n=314) and patients with AF without COPD (n=10818).

### **Data collection and definition**

Researchers at each center involved in this study retrieved patients with AF through the hospital medical information system and conducted follow-ups with patients or their families to ascertain clinical outcomes. The data collected included demographic information (such as age, gender, BMI, smoking, alcohol consumption, etc.), biochemical indicators (such as total bilirubin, alanine transaminase, aspartate transaminase, albumin, etc.), information on comorbidities (such as hypertension, diabetes, coronary heart disease, vascular diseases, etc.), and information on concomitant medications (such as statins, antiplatelet drugs, PPIs, etc.). Before follow-up, we standardized the follow-up questions and strictly defined each clinical event. The follow-up period was defined as from the start date of oral anticoagulant therapy to the stop date of oral

anticoagulant therapy or the end date of the study. Identification and diagnosis of COPD were primarily based on physician-established diagnoses recorded in the hospital electronic medical record (EMR) system. Bleeding events were ascertained from (i) the hospital EMR during inpatient or outpatient encounters and (ii) telephone follow-up after discharge. We prioritized objective chart documentation when ascertaining bleeding; for out-of-hospital bleeding reported during follow-up, we sought to obtain supporting medical records for verification whenever feasible. Additionally, based on the clinical data of the patients, we assessed the patients' CHA2DS2-VASC score[21] (including congestive heart failure/left ventricular dysfunction, hypertension, age  $\geq 75$  years, diabetes, stroke or transient ischemic attack, vascular disease, age 65-74 years, female gender) and HAS-BLED score (hypertension, abnormal liver function, abnormal renal function, stroke, bleeding, age  $> 65$  years, drugs and alcohol). The primary exposures were (i) presence of COPD and (ii) oral anticoagulant class, warfarin vs DOACs; DOACs further categorized as FXa inhibitors (rivaroxaban, apixaban, edoxaban) and dabigatran.

### **Study outcomes**

The main outcome events of this study were total bleeding, major bleeding, minor bleeding, all-cause death events and Net adverse clinical events (NACE), defined as a composite endpoint of thromboembolic events or major bleeding (counted as positive if either component occurred) .

According to the definition by the International Society on Thrombosis and Haemostasis (ISTH), major bleeding refers to bleeding that leads to death, occurs in a critical organ (intracranial, intraspinal, intraocular, retroperitoneal, intra-articular, or pericardial, or involves compartment

syndrome), or results in a decrease in hemoglobin levels of at least 2g/dl or the transfusion of at least two units of whole blood or red cells[22]. Minor bleeding was defined as any overt bleeding that did not meet the International Society on Thrombosis and Haemostasis (ISTH) criteria for major bleeding and did not fulfill the ISTH criteria for clinically relevant non-major bleeding (CRNMB)[23]. Thromboembolic events included ischemic stroke and systemic embolism (SE). SE was defined as acute vascular occlusion of an extremity or organ confirmed by imaging, surgery, or autopsy[24]. Total bleeding includes all bleeding events (major and minor). All suspected bleeding and thromboembolic events were classified according to ISTH criteria, with objective documentation in the medical record serving as the primary source of confirmation. For out-of-hospital events identified solely via telephone follow-up, we sought to retrieve medical evidence for verification whenever feasible. All study endpoints were assessed for occurrence over the entire follow-up period. Bleeding and NACE were treated as binary outcomes. Owing to the lack of precise event-time data, all-cause death was likewise analyzed as a binary outcome, defined as any death occurring from cohort entry through the end of follow-up.

### **Statistical Analysis**

Continuous variables were assessed for normality. Normally distributed data are presented as mean  $\pm$  standard deviation (SD) and compared using Student's t test; non-normally distributed data are summarized as median (interquartile range [IQR]) and compared using the Mann–Whitney U test. Categorical variables are presented as counts and percentages and compared using the  $\chi^2$  test. To evaluate the impact of COPD on bleeding, all-cause mortality, and NACE,

we analyzed the overall AF cohort (n=11,132) using COPD status as the exposure and applied propensity score overlap weighting (OW) with overlap-weighted logistic regression as the primary approach. As sensitivity analyses, we performed 1:1 propensity score matching (PSM) and re-estimated OR/AR/RD to assess consistency across causal inference strategies.

In the AF with comorbid COPD subcohort (n=314), with exposure defined as DOAC versus warfarin, the primary analysis likewise used OW with overlap-weighted logistic regression.

Covariate balance was assessed using the absolute standardized mean difference (SMD) with a threshold of 0.10; any covariate with residual imbalance ( $|SMD| > 0.10$ ) was included in the weighted outcome model. We reported aORs and ARs/RDs with 95% CIs obtained via marginal standardization (g-computation). Sensitivity analyses comprised: (i) an unweighted multivariable logistic regression; (ii) logistic regression with inverse probability of treatment weighting (IPTW); and (iii) a restriction excluding baseline concomitant antiplatelet therapy. To address rare events or separation, we used cluster-robust standard errors by center and, when necessary, applied Firth-penalized logistic regression and mixed-effects logistic regression (center as a random intercept) as fallback models.

Within the AF with comorbid COPD cohort, using OW we further evaluated: (i) effectiveness and safety stratified by renal function (DOAC vs warfarin); and (ii) among patients treated with DOAC, an exploratory comparison of FXa inhibitors versus dabigatran. Each subgroup reported aOR and AR/RD (95% CI). When the RD and its 95% CI were directionally concordant and clinically interpretable, we calculated the numbers needed to treat and to harm (NNT/NNH). All

statistical analyses were conducted in R (version 4.4.3).

## Results

### Baseline characteristics

The baseline characteristics of AF patients on anticoagulant therapy, with and without COPD, are shown in Supplementary Table 2. Compared with the AF-only group (n=10,818), the AF with comorbid COPD group (n=314) was older, had a higher proportion of men, and a lower BMI; it also carried a greater comorbidity burden, with heart failure, coronary artery disease, and prior stroke being more common. Overall use of oral anticoagulation was significantly lower. In laboratory indices, total bilirubin (TBil), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) were lower, whereas serum creatinine was higher; platelet counts did not differ significantly. Regarding medications, use of digoxin and nonsteroidal anti-inflammatory drugs (NSAIDs) was more frequent, whereas  $\beta$ -blockers and calcium channel blockers (CCBs) were used less often; the use of antiplatelet agents, statins, and angiotensin II receptor blockers (ARBs) was similar. Risk scores (HAS-BLED and CHA<sub>2</sub>DS<sub>2</sub>-VASc) were higher. Except for smoking status and platelet count, most between-group differences were statistically significant (p<0.05). Within the COPD group, baseline characteristics between patients treated with warfarin (43 patients) and direct oral anticoagulant (271 patients) were compared among a total of 314 patients (Table 1). No differences were found between the two subgroups in terms of gender, age, BMI, smoking, other comorbidities, laboratory indicators, bleeding risk (Has-Bled score), and stroke risk (CHA<sub>2</sub>DS<sub>2</sub>-VASc score). In terms of concomitant medication, compared to the

warfarin group, patients on DOACs were more likely to also receive anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), proton pump inhibitors (PPIs), angiotensin receptor blockers (ARBs), and  $\beta$ -blockers, with statistically significant differences ( $p < 0.05$ ). Event counts for the full cohort, stratified by anticoagulant, are shown in Supplementary Table 3.

### **Impact of COPD on Clinical Outcomes in Patients with AF**

In the overlap-weighted primary analysis stratified by anticoagulation strategy (warfarin vs DOACs), COPD was associated with a higher bleeding risk among patients treated with warfarin : total bleeding OR 2.53 (95% CI, 1.00–6.45), corresponding RD 9.05% (95% CI, 0.15%–22.50%); minor bleeding OR 3.00 (1.09–8.24), RD 8.53% (0.56%–21.53%). In the DOAC group, these associations were not significant. No significant associations were observed for major bleeding, all-cause death, or NACE in either anticoagulation stratum. The treatment-by-disease interaction was borderline and not statistically significant for total bleeding ( $P = 0.057$ ) and minor bleeding ( $P = 0.061$ ) (Figure 2). Overlap-weighted event counts and absolute risks are shown in Supplementary Table 4.

Covariate balance assessment indicated that OW reduced all covariate |SMD| values to  $<0.10$ ; PSM (1:1) generally met the threshold, although several variables showed residual imbalance. Baseline differences between matched-included and matched-excluded patients are provided in Supplementary Table 5. In the unweighted sample, there were pronounced imbalances in age, anticoagulant type, creatinine, HAS-BLED score, heart failure, coronary artery disease, BMI, and albumin (Supplementary Figure 1). Accordingly, OW was selected as the primary analysis to

enhance the robustness of the effect estimates.

As sensitivity analyses, the crude model and PSM (1:1) yielded results consistent with the primary findings: among patients treated with warfarin, COPD was associated with higher risks of overall and minor bleeding, whereas no such associations were observed among DOAC; and there were no consistent significant associations with major bleeding, all-cause death, or NACE. The interaction for overall and minor bleeding was borderline in these sensitivity analyses as well, with directions concordant with the primary analysis (Supplementary Table 6).

### **Impact of Oral Anticoagulants on Clinical Outcomes in Patients with AF and COPD**

In patients with AF and COPD, the OW-adjusted primary analysis (Model 2) showed that, compared with warfarin, DOACs were associated with a lower risk of total bleeding (OR, 0.08; 95% CI, 0.01–0.50; RD, –8.4%; 95% CI, –22.0% to –5.3%). Minor bleeding was likewise reduced (OR 0.01; RD, –9.5%; 95% CI, –23.1% to –4.5%), although the CIs were wide.

Estimates for major bleeding were unstable because of sparse data (near-zero weighted events in the treatment arm); the overlap-weighted event counts are provided in Supplementary Table 7.

The RD for major bleeding was close to zero, with CIs crossing the null. No clear differences were observed for all-cause death or NACE.

Model 1 (crude; unweighted and unadjusted) showed no statistically significant differences for any endpoint, but the trends for overall and minor bleeding (OR <1) were consistent with the primary analysis (Table 2). As sensitivity analyses, Model 3 (unweighted but covariate-adjusted) demonstrated significant advantages of DOACs in reducing total bleeding (OR, 0.27) and minor

bleeding (OR, 0.18), further supporting the primary findings. Model 4 (IPTW) yielded results concordant with the primary analysis, again confirming the advantages of DOACs for overall and minor bleeding (OR, 0.21 and 0.09, respectively). Model 5 (OW excluding patients on baseline antiplatelet therapy) was markedly affected by sparse data, rendering several outcomes (e.g., major bleeding) non-estimable or yielding aberrant ORs, reflecting reduced statistical power after the restriction; nonetheless, the RDs were directionally and quantitatively similar to the other models. Across methods, all-cause death and NACE showed no stable differences (effects near zero with wide CIs), as detailed in Supplementary Table 8. Balance diagnostics (Supplementary Figure 2) indicated that OW achieved  $|\text{SMD}| \leq 0.10$  for all covariates, IPTW performed second best, and substantial imbalances persisted in the unweighted sample.

### Subgroup Analyses

Based on the propensity score overlap-weighted model, a subgroup analysis stratified by baseline renal function (eGFR) demonstrated a significant interaction for all-cause death (P for interaction = 0.006). Among patients with  $\text{eGFR} \geq 60 \text{ mL/min/1.73 m}^2$ , DOACs were associated with a higher risk of all-cause death compared with warfarin (OR, 3.07; 95% CI, 0.78–12.03; RD, 9.9%). In contrast, among those with  $\text{eGFR} < 60 \text{ mL/min/1.73 m}^2$ , DOACs were associated with a significantly lower mortality risk (OR, 0.20; 95% CI, 0.05–0.78; RD, –24.1%). For overall and minor bleeding, DOACs showed lower risks in both strata with negative RDs, and interaction P-values  $> 0.05$ . Major bleeding did not differ significantly between DOACs and warfarin in either stratum. The direction of the composite endpoint NACE paralleled that of all-cause death,

although the interaction was not significant ( $P = 0.119$ ). Detailed ORs and RDs are presented in Figure 3, and overlap-weighted event counts and absolute risks (ARs) are summarized in Supplementary Table 9.

In the AF with comorbid COPD population restricted to DOAC, an overlap-weighted model with adjustment for residually imbalanced covariates compared FXa inhibitors (apixaban/rivaroxaban/edoxaban) versus dabigatran. Major bleeding was significantly higher with FXa inhibitors (OR, 4.56; 95% CI, 1.70–12.26; RD, 10.2%; 95% CI, 0.2%–20.1%), corresponding to an NNH of 10 (95% CI, 5–487). Total bleeding trended higher but was not significant (OR, 2.17; 95% CI, 0.51–9.19; RD, 8.6%; 95% CI, –5.4% to 22.7%). Minor bleeding, all-cause death, and NACE did not differ significantly (ORs 0.81, 1.32, and 1.31, respectively; corresponding RDs –1.5%, +3.9%, and +3.4%, with 95% CIs spanning the null). Detailed ORs and RDs are presented in Figure 4, and overlap-weighted event counts and ARs are shown in Supplementary Table 10.

## Discussion

This study is a multicenter retrospective cohort study based on 12 hospitals in China, aimed at comparing the risks of bleeding and all-cause death between warfarin and DOACs in patients with AF and COPD undergoing anticoagulation therapy. We used propensity score overlap-weighted (ATO) logistic regression as the primary analytic framework, reported ARs and RDs with 95%CI and accordingly derived the NNH. Sensitivity analyses were performed to enhance the robustness of inference.

The main findings are as follows: (i) In overlap-weighted, anticoagulant-stratified analyses (with concordant sensitivity checks), COPD was linked to higher bleeding risk only among warfarin; major bleeding, all-cause death, and NACE showed no consistent associations, and the treatment-by-disease interaction for bleeding was borderline. (ii) Within AF and COPD, DOACs vs warfarin reduced overall and minor bleeding, with no stable differences for major bleeding, all-cause death, or NACE (major bleeding estimates were unstable due to rarity).

(iii) Renal function modified the death effect: DOACs lowered mortality for  $eGFR < 60$  mL/min/1.73 m<sup>2</sup>, with no advantage at  $eGFR \geq 60$  mL/min/1.73 m<sup>2</sup>. (iv) Among DOAC, FXa inhibitors vs dabigatran increased major bleeding, while other endpoints were similar.

In line with our findings, Romiti[7] and others have found that patients with COPD have higher risks of all-cause death and bleeding. A 2018 study[16] indicated that COPD adversely affects the prognosis of AF patients, increasing the risks of all-cause death, cardiovascular disease hospitalization, and cardiovascular death. COPD patients often have additional risk factors such as smoking, old age, comorbidities, and concomitant medications that may increase bleeding risks. Smoking is not only a key risk factor for COPD but also shows causal and dose-response relationships with the initiation, perpetuation, and recurrence of AF. A recent study reported that for every additional 10 cigarettes smoked per day, AF risk increases by approximately 14% [25], suggesting that smoking promotes arrhythmogenesis and thrombogenicity via inflammatory mechanisms, atrial structural remodeling, and electrophysiological pathways. The impact of smoking on warfarin is relatively well established: polycyclic aromatic hydrocarbons in tobacco

smoke induce CYP1A2 and other enzymes, accelerating metabolism (principally of the R-warfarin enantiomer), thereby increasing maintenance dose requirements and attenuating anticoagulant effect[26]. A meta-analysis estimated that smokers require, on average, a 12% higher warfarin maintenance dose; moreover, INR should be closely monitored and doses adjusted when patients quit smoking or change smoking intensity—an issue of particular relevance in COPD populations with fluctuating tobacco exposure[27]. For DOACs, direct evidence that smoking per se alters drug exposure is limited. However, during acute COPD exacerbations, patients frequently receive macrolide or fluoroquinolone antibiotics and other agents, some of which are strong or moderate CYP3A4 inhibitors or inducers. These drug–drug interactions can substantially modify exposure to apixaban and rivaroxaban and increase bleeding risk (e.g., higher bleeding risk with concomitant clarithromycin). Thus, in real-world care of smokers with COPD, indirect interaction pathways warrant heightened vigilance[28].

Since the introduction of DOACs (DOACs), many clinical studies and meta-analyses have shown that the efficacy and safety of DOACs are comparable or even superior to warfarin in patients with AF, including those with additional comorbidities[29,30]. Although current guidelines and the Global Initiative for Chronic Obstructive Lung Disease support anticoagulation therapy for patients with AECOPD, a consensus on prophylactic anticoagulation therapy for COPD patients has not yet been reached[9]. From the standpoint of biological plausibility, some investigators have hypothesized that vitamin K antagonists (VKAs) may be linked to vascular calcification by impairing activation of extrahepatic vitamin K–dependent

proteins such as matrix Gla protein (MGP), whereas DOACs do not act through this pathway[31–34]. However, this study did not capture key information—warfarin time in therapeutic range (TTR), DOAC dose appropriateness, or vascular imaging/biomarker data—needed to evaluate that mechanism. Accordingly, these considerations are offered solely as hypothesis-generating background, not as causal explanations or as a basis for our conclusions, and they require prospective validation.

Our study drew on a multicenter, real-world cohort. We used propensity score overlap weighting to enhance comparability and reported marginal (g-computation) and absolute effects (ARs/RDs), alongside harmonized methodological sensitivity analyses and key subgroup analyses within a unified framework; directions of effect were concordant. Nevertheless, several limitations merit consideration. First, endpoint ascertainment relied on in-hospital electronic medical records and post-discharge telephone follow-up. We prioritized objective chart documentation and, whenever possible, retrieved emergency/outpatient records and laboratory reports for verification; discrepant cases were reviewed by a second investigator. However, recall bias may persist for out-of-hospital events lacking complete documentation, and adjudication was not fully blinded. Second, the database lacked key clinical variables, limiting confounding control and assessment of prescribing quality. Third, sparse events and diminished overlap in certain subgroups/outcomes yielded unstable estimates with wide confidence intervals; moreover, the absence of precise event-time data precluded time-to-event analyses, restricting us to odds ratios and absolute risks over the follow-up period. Finally, as an observational study,

residual and unmeasured confounding cannot be excluded, and generalization should be made cautiously.

### Conclusion

Among anticoagulated patients with AF and COPD, overlap-weighted (ATO) analyses showed that DOACs, compared with warfarin, were associated with lower risks of overall and minor bleeding, with no clear differences in major bleeding, all-cause mortality, or NACE. The effect on mortality differed by renal function: a benefit was observed at  $eGFR < 60 \text{ mL/min/1.73 m}^2$  but not at  $eGFR \geq 60 \text{ mL/min/1.73 m}^2$ . Within the DOAC class, Fxa inhibitor were associated with a higher risk of major bleeding than dabigatran. These findings support preferential use of DOACs to minimize bleeding, suggest a possible survival benefit in renal impairment, and warrant prospective confirmation; agent selection should consider NNH and individual patient factors.

## Acknowledgements

**Author contributions:** Na Zhao and Ting Wei contributed equally to the conception and design of the study, data acquisition, analysis and interpretation, and drafting the manuscript. Xinhai Huang, Guilan Wu, Ruijuan Li, Qiaowei Zheng, Xiumei Liu, Hengfen Dai, Xiangsheng Lin, Yuxin Liu, Jun Su, Xiaomin Dong, Cuifang You, Shuzheng Jiang, and Yanxian Lan contributed to data acquisition and critical revision of the manuscript. Jinhua Zhang contributed to the conception and design, supervision of the study, and critical revision of the manuscript. All authors approved the final version.

**Data sharing statement:** The data sets used and/or analyzed for the study described in this manuscript are available upon reasonable request. Qualified researchers may request access to patient level data and related study documents including the study protocol and the statistical analysis plan. Patient level data will be deidentified and study documents will be redacted to protect the privacy of trial participants and to protect commercially confidential information.

**Declaration of interests:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Pre-proof

## References

- [1] Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: A report of the American college of cardiology/american heart association joint committee on clinical practice guidelines. *Circulation* 2024;149:e1–156. <https://doi.org/10.1161/CIR.0000000000001193>.
- [2] Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A global burden of disease 2010 study. *Circulation* 2014;129:837–47. <https://doi.org/10.1161/CIRCULATIONAHA.113.005119>.
- [3] Escudero-Martínez I, Morales-Caba L, Segura T. Atrial fibrillation and stroke: A review and new insights. *Trends Cardiovasc Med* 2023;33:23–9. <https://doi.org/10.1016/j.tcm.2021.12.001>.
- [4] Jf M, C B, B B-A, et al. Guidelines for the primary prevention of stroke: A statement for healthcare professionals from the American heart association/american stroke association. *Stroke* 2014;45. <https://doi.org/10.1161/STR.0000000000000046>.
- [5] Cervera A, Amaro S, Chamorro A. Oral anticoagulant-associated intracerebral hemorrhage. *J Neurol* 2012;259:212–24. <https://doi.org/10.1007/s00415-011-6153-3>.
- [6] Levine M, Hirsh J. Hemorrhagic complications of long-term anticoagulant therapy for ischemic cerebral vascular disease. *Stroke* 1986;17:111–6. <https://doi.org/10.1161/01.str.17.1.111>.
- [7] Romiti GF, Corica B, Pipitone E, et al. Prevalence, management and impact of chronic obstructive pulmonary disease in atrial fibrillation: A systematic review and meta-analysis of 4,200,000 patients. *Eur Heart J* 2021;42:3541–54. <https://doi.org/10.1093/eurheartj/ehab453>.
- [8] Ye J, Yao P, Shi X, et al. A systematic literature review and meta-analysis on the impact of COPD on atrial fibrillation patient outcome. *Heart Lung: J Crit Care* 2022;51:67–74. <https://doi.org/10.1016/j.hrtlng.2021.09.001>.
- [9] GOLD (2024) GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE. Global

- Initiative for Chronic Obstructive Lung Disease - GOLD n.d. [https://goldcopd.org/wp-content/uploads/2024/02/GOLD-2024\\_v1.2-11Jan24\\_WMV.pdf](https://goldcopd.org/wp-content/uploads/2024/02/GOLD-2024_v1.2-11Jan24_WMV.pdf) (accessed November 8, 2025).
- [10] Sinden NJ, Stockley RA. Systemic inflammation and comorbidity in COPD: A result of “overspill” of inflammatory mediators from the lungs? Review of the evidence. *Thorax* 2010;65:930–6. <https://doi.org/10.1136/thx.2009.130260>.
- [11] Yi T, HJ K-N, K M. Infections and inflammatory diseases as risk factors for venous thrombosis. A systematic review. *Thromb Haemost* 2012;107. <https://doi.org/10.1160/TH11-09-0611>.
- [12] Gunen H, Gulbas G, In E, et al. Venous thromboemboli and exacerbations of COPD. *Eur Respir J* 2010;35:1243–8. <https://doi.org/10.1183/09031936.00120909>.
- [13] Chen W-J, Lin C-C, Lin C-Y, et al. Pulmonary embolism in chronic obstructive pulmonary disease: A population-based cohort study. *Copd* 2014;11:438–43. <https://doi.org/10.3109/15412555.2013.813927>.
- [14] Petris OR, Cojocaru E, Fildan AP, et al. COPD and anticoagulation therapy: Time for a new approach? *Int J Chronic Obstr Pulm Dis* 2021;16:3429–36. <https://doi.org/10.2147/COPD.S340129>.
- [15] Local and systemic cellular inflammation and cytokine release in chronic obstructive pulmonary disease. *Cytokine* 2011;56:298–304. <https://doi.org/10.1016/j.cyto.2011.07.010>.
- [16] Durham MT, Holmes DN, Blanco RG, et al. Characteristics and outcomes of adults with chronic obstructive pulmonary disease and atrial fibrillation. *Heart* 2018;104:1850–8. <https://doi.org/10.1136/heartjnl-2017-312735>.
- [17] Huang X, Xu W, Wu G, et al. Efficacy and safety of dabigatran and rivaroxaban in atrial fibrillation patients with impaired liver function: A multicenter retrospective cohort study. *Eur J Clin Pharmacol* 2024;80:1141–50. <https://doi.org/10.1007/s00228-024-03689-3>.
- [18] Li Y, Wu S, Zhou J, et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with chronic kidney disease: A systematic review and meta-

- analysis. *Thromb J* 2024;22:40. <https://doi.org/10.1186/s12959-024-00608-5>.
- [19] Guan C, Xu W, Lv M, et al. Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation combined with hypertension: A multicenter, retrospective cohort study. *J Clin Pharmacol* 2023;63:895–902. <https://doi.org/10.1002/jcph.2246>.
- [20] Zhang H, Xue Z, Yi D, et al. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation with coronary or peripheral artery disease. *Int Heart J* 2020;61:231–8. <https://doi.org/10.1536/ihj.19-202>.
- [21] Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. *J Thromb Haemost* 2005;3:692–4. <https://doi.org/10.1111/j.1538-7836.2005.01204.x>.
- [22] Kaatz S, Ahmad D, Spyropoulos AC, et al. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. *J Thromb Haemost* 2015;13:2119–26. <https://doi.org/10.1111/jth.13140>.
- [23] Lip GYH, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: The euro heart survey on atrial fibrillation. *Chest* 2010;137:263–72. <https://doi.org/10.1378/chest.09-1584>.
- [24] Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med* 2009;361:1139–51. <https://doi.org/10.1056/NEJMoa0905561>.
- [25] Wu Z, Tang C, Wang D. Bidirectional two-sample mendelian randomization study of association between smoking initiation and atrial fibrillation. *Tob Induced Dis* 2024;22. <https://doi.org/10.18332/tid/189380>.
- [26] Lucas C, Martin J. Smoking and drug interactions. *Aust Prescr* 2013;36:102–4. <https://doi.org/10.18773/austprescr.2013.037>.
- [27] Nathisuwan S, Dilokthornsakul P, Chaiyakunapruk N, et al. Assessing evidence of

- interaction between smoking and warfarin: A systematic review and meta-analysis. *Chest* 2011;139:1130–9. <https://doi.org/10.1378/chest.10-0777>.
- [28] Mar PL, Gopinathannair R, Gengler BE, et al. Drug interactions affecting oral anticoagulant use. *Circ: Arrhythmia Electrophysiol* 2022;15:e007956. <https://doi.org/10.1161/CIRCEP.121.007956>.
- [29] Harrington J, Carnicelli AP, Hua K, et al. Direct oral anticoagulants versus warfarin across the spectrum of kidney function: Patient-level network meta-analyses from COMBINE AF. *Circulation* 2023;147:1748–57. <https://doi.org/10.1161/CIRCULATIONAHA.122.062752>.
- [30] Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: Patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. *Circulation* 2022;145:242–55. <https://doi.org/10.1161/CIRCULATIONAHA.121.056355>.
- [31] Piscoer I, Wouters EFM, Vermeer C, et al. Vitamin K deficiency: The linking pin between COPD and cardiovascular diseases? *Respir Res* 2017;18:189. <https://doi.org/10.1186/s12931-017-0673-z>.
- [32] Williams MC, Murchison JT, Edwards LD, et al. Coronary artery calcification is increased in patients with COPD and associated with increased morbidity and mortality. *Thorax* 2014;69:718–23. <https://doi.org/10.1136/thoraxjnl-2012-203151>.
- [33] Luo G, Ducey P, McKee MD, et al. Spontaneous calcification of arteries and cartilage in mice lacking matrix GLA protein. *Nature* 1997;386:78–81. <https://doi.org/10.1038/386078a0>.
- [34] Bouvet C, Moreau S, Blanchette J, et al. Sequential activation of matrix metalloproteinase 9 and transforming growth factor  $\beta$  in arterial elastocalcinosis. *Arterioscler, Thromb, Vasc Biol* 2008;28:856–62. <https://doi.org/10.1161/ATVBAHA.107.153056>.

Table 1. Baseline characteristics of patients with atrial fibrillation and COPD

Characteristic	Total (n=314)	Warfarin (n=43)	DOACs (n=271)	P value
sex, male, n (%)	80 (25)	12 (28)	68 (25)	0.837
age, median[IQR]	76 [70, 82]	76 [68, 79.5]	76 (70.5, 82]	0.102
BMI, median[IQR]	23.22[21.48, 24.84]	23.51[21.36, 24.63]	23.12[21.48, 24.95]	0.932
smoking, n (%)	134 (43)	19 (44)	115 (42)	0.96
drinking, n (%)	89 (28)	12 (28)	77 (28)	1
hypertension, n (%)	180 (57)	23 (53)	157 (58)	0.703
diabetes, n (%)	82 (26)	9 (21)	73 (27)	0.518
HF, n (%)	170 (54)	27 (63)	143 (53)	0.289
gout, n (%)	23 (7)	2 (5)	21 (8)	0.752
stroke, n (%)	64 (20)	8 (19)	56 (21)	0.914
CHD, n (%)	148 (47)	14 (33)	134 (49)	0.058
TIA, n (%)	18 (6)	1 (2)	17 (6)	0.485
hepatic insufficiency, n (%)	9 (3)	1 (2)	8 (3)	1
renal insufficiency, n (%)	37 (12)	8 (19)	29 (11)	0.215
TBil, median[IQR]	13.4[8.72, 19.45]	15.5[9, 24.3]	13[8.75, 18.8]	0.298
albumin, median[IQR]	37.85[33.62, 40.5]	36.7[34.45, 40.2]	38.1[33.55, 40.6]	0.67
ALT, median[IQR]	19[13, 28.98]	19[12, 31]	19[13, 28.8]	0.848
AST, median[IQR]	24.5[19, 33.98]	28[22, 33.5]	24[18.05, 33.95]	0.068
ALP, median[IQR]	78[63.1, 90.97]	80.1[68, 111.5]	77.3[63, 89]	0.06
creatinine, median[IQR]	89.5[75, 115]	89[75.5, 117.5]	89.5[75, 114.5]	0.956
PLT, median[IQR]	195.5[158, 240]	194[148, 264]	196[160, 239]	0.82
Hb, median[IQR]	128[115, 140]	122[109, 142.5]	128[116, 139]	0.469
antiplatelet, n (%)	103 (33)	17 (40)	86 (32)	0.402
anticoagulation, n (%)	46 (15)	17 (40)	29 (11)	< 0.001
NSAIDs, n (%)	40 (13)	14 (33)	26 (10)	< 0.001
PPI, n (%)	150 (48)	32 (74)	118 (44)	< 0.001
statins, n (%)	180 (57)	25 (58)	155 (57)	1
ARB, n (%)	94 (30)	19 (44)	75 (28)	0.044
β-blocker, n (%)	162 (52)	29 (67)	133 (49)	0.038
CCB, n (%)	62 (20)	11 (26)	51 (19)	0.407
Digoxin, n (%)	81(26)	14(33)	67(25)	0.366
Has-Bled , median[IQR]	2[1,2]	1[1,2]	2[1,2]	0.423
CHA2DS2-VASc, median[IQR]	4[3,5]	4[3,6]	4[3,5]	0.779

Footnotes: Values are median (interquartile range) except as noted

COPD: Chronic obstructive pulmonary disease, BMI: Body mass index, HF: Heart failure, CHD: coronary heart disease, TIA: Transient ischemic attack, DOACs: Direct oral anticoagulants, TBil: total bilirubin, ALT: Alanine transaminase, AST: Aspartate transaminase, ALP: Alkaline

phosphatase, PLT: Platelet count, Hb: Hemoglobin, NSAIDs: Nonsteroidal antiinflammatory drugs, PPI: Proton pump inhibitor, ARB: Angiotensin receptor blockers, CCB: Calcium entry blockers

Pre-proof

Table 2. Comparison of DOAC vs Warfarin in Patients with Atrial Fibrillation and COPD: Odds Ratios (OR) and Risk Differences (RD)

Outcomes	Model 1 <sup>a</sup>			Model 2 <sup>b</sup>		
	OR(95%CI)	P Value	RD(95%CI) <sup>c</sup>	OR(95%CI)	P Value	RD(95%CI)
Total bleeding	0.52(0.20 -1.37)	0.19	-6.2(-17.1 to 4.6)	0.08(0.01 -0.50)	0.01	-8.4(-22 to 5.3)
Major bleeding	1.44(0.18 -11.7)	0.73	1.0(-4.0 to 6.0)	2442.23(8.03 -742975.14) <sup>d</sup>	0.01	1.1(-0.2 to 2.4)
Minor bleeding	0.35(0.12 -1.06)	0.06	-7.2(-17.1 to 2.7)	0.01(0 -0.88)	0.04	-9.5(-23.1 to 4.2)
All-cause death	0.86(0.33 -2.18)	0.74	-1.8(-12.9 to 9.3)	1.03(0.26 -4.11)	0.97	0.9(-9.3 to 11.1)
NACE <sup>e</sup>	2.64(0.34 -20.47)	0.35	3.6(-1.7 to 8.9)	0.20(0 -11.86)	0.44	2.5(-0.1 to 5.1)

a. Footnotes:

b. a.Model 1 (unweighted, crude): logistic regression with treatment only; no covariates. Odds ratios (OR) are reported; risk difference (RD) is estimated using an identity-link linear probability model.

c. b.Model 2 (overlap-weighted, adjusted): propensity-score overlap weighting (ATO) with probit PS; 1% weight truncation; post-weighting residually imbalanced covariates ( $|SMD| > 0.10$ ), robust (design-based) SEs were used.


d. c.RD (95% CI): RD is expressed as absolute risk difference (%) without the percentage symbol, defined as DOAC – warfarin (attributable risk in DOAC minus attributable risk in warfarin); negative values favor DOAC.

e. d.The extremely large OR reflects sparse-data/(quasi-)complete separation after overlap weighting (with antiplatelet exclusion): the (weighted) event count in one arm was ~0, with very small effective sample size (ESS) and minimum weighted cell <5, causing the logit coefficient to diverge and the OR/CI to inflate.


f. e. NACE (net adverse clinical events) : Thrombosis event or major bleeding (composite).

**Figure captions:**

**Figure 1. Participant inclusion flowchart.**



**Figure 2. COPD–outcome associations within anticoagulant strata (overlap-weighted analysis).**




Footnotes:

OR(95%CI) are adjusted odds ratios from overlap-weighted logistic regressions targeting the ATO (average treatment effect in the overlap) population with robust SEs.

RD(95%CI) are adjusted absolute risk differences (percentage points) obtained by marginal standardization of the same models. Positive RD indicates a higher absolute risk in COPD.

**Figure 3. Renal-function–stratified effects of DOACs versus warfarin in AF with COPD (overlap-weighted analysis).**




Footnotes:

Estimates compare DOACs vs warfarin within the AF+COPD subcohort, eGFR strata: ≥60 and <60 mL/min/1.73 m<sup>2</sup>.

OR (95% CI): adjusted odds ratios from overlap-weighted (ATO target) logistic regression with robust SEs.

RD (95% CI), %: marginal standardized absolute risk differences (percentage points) from the same models. Negative RD favors DOACs (lower absolute risk vs warfarin); positive RD favors warfarin.

**Figure 4. Within-DOAC comparison in AF with COPD: FXa inhibitors vs dabigatran (overlap-weighted analysis).**



**Footnotes:**

Estimates compare factor Xa inhibitors (apixaban/rivaroxaban/edoxaban, pooled) vs dabigatran (reference) within the AF with COPD subcohort.

OR (95% CI): adjusted odds ratios from overlap-weighted (ATO target) logistic regression with robust SEs

RD (95% CI), %: marginal standardized absolute risk differences (percentage points) from the same models. Positive RD indicates higher absolute risk with FXa inhibitors (favors dabigatran); negative RD favors FXa inhibitors.

NNH/NNT (95% CI): derived as  $1/|RD|$  (per 100 treated); shown only when the RD 95% CI excludes 0. “NNH” is reported when FXa is harmful ( $RD > 0$ ); “NNT” when FXa is beneficial ( $RD < 0$ ).

## Online Supplement

**Supplemental Table 1. List of 12 multi-center hospitals**

Number	Institutes	Investigators	City
1	Shanxi Bethune Hospital	Ruijuan Li	Taiyuan
2	First Affiliated Hospital of Xi'an Jiaotong University	Qiaowei Zheng	Xi'an
3	People's Hospital of He'nan University of Chinese Medicine	Xiumei Liu	Zhengzhou
4	Affiliated Fuzhou First Hospital of Fujian Medical University	Hengfen Dai	Fuzhou
5	Pingtang County General Laboratory Area Hospital	Xiangsheng Lin	Fuzhou
6	Huaihe Hospital of Henan University, kaifeng	Yuxin Liu	Kaifeng
7	Department of Pharmacy, the First Affiliated Hospital of Bengbu Medical College	Jun Su	Bengbu
8	Department of Pharmacy, Fujian Maternity and Child Health Hospital	Jinhua Zhang	Fuzhou
9	Affiliated Hospital of Guilin Medical University	Xiaomin Dong	Guilin
10	Ningde Municipal Hospital Affiliated to Ningde Normal University	Cuifang You	Ningde
11	Wuhan Hospital of Traditional Chinese and Western Medicine	Shuzheng Jiang	Wuhan
12	Minzu Hospital of Guangxi Zhuang Autonomous Region	Yanxian Lan	Nanning

**Supplementary Table 2. Baseline characteristics of atrial fibrillation patients with and without COPD (unweighted)**

Pre-proof

Footnotes: Values are median (interquartile range) except as noted

COPD: Chronic obstructive pulmonary disease, BMI: Body mass index, HF: Heart failure, CHD: coronary heart disease, TIA: Transient ischemic attack, DOACs: Direct oral anticoagulants, TBil: total bilirubin, ALT: Alanine

Characteristic	AF-only(N=10818)	AF+COPD(N=314)	P-value	SMD
sex,male(%)	6292 (58.2)	234 (74.5)	<0.001	0.352
age,median[IQR]	67.00 [59.00, 75.00]	76.00 [70.00, 82.00]	<0.001	0.873
BMI,median[IQR]	24.22 [21.88, 26.37]	23.22 [21.48, 24.84]	<0.001	0.254
smoking(%)	4094 (37.8)	134 (42.7)	0.093	0.099
drinking(%)	2641 (24.4)	89 (28.3)	0.126	0.089
hypertension(%)	7277 (67.3)	180 (57.3)	<0.001	0.206
diabetes(%)	2558 (23.6)	82 (26.1)	0.344	0.057
HF(%)	2708 (25.0)	170 (54.1)	<0.001	0.623
gout(%)	354 (3.3)	23 (7.3)	<0.001	0.182
stroke(%)	1644 (15.2)	64 (20.4)	0.015	0.136
CHD(%)	2219 (20.5)	148 (47.1)	<0.001	0.586
TIA(%)	386 (3.6)	18 (5.7)	0.062	0.103
hepatic insufficiency(%)	327 (3.0)	9 (2.9)	1.000	0.009
renal insufficiency(%)	1043 (9.6)	37 (11.8)	0.243	0.069
TBil,median[IQR]	15.40 [10.62, 17.90]	13.40 [8.72, 19.45]	0.006	0.037
albumin,median[IQR]	38.50 [36.40, 40.80]	37.85 [33.62, 40.50]	<0.001	0.204
ALT,median[IQR]	22.00 [14.00, 29.40]	19.00 [13.00, 28.98]	0.002	0.059
AST,median[IQR]	28.00 [20.00, 40.10]	24.50 [19.00, 33.98]	<0.001	0.010
ALP,median[IQR]	82.00 [65.00, 89.00]	78.00 [63.10, 90.97]	0.416	0.017
creatinine,median[IQR]	85.00 [69.00, 94.00]	89.50 [75.00, 115.00]	<0.001	0.319
PLT,median[IQR]	199.15 [157.00, 226.67]	195.50 [158.00, 240.00]	0.387	0.134
Hb,median[IQR]	131.60 [122.00, 143.00]	128.00 [115.00, 140.00]	<0.001	0.269
antiplatelet(%)	3359 (31.1)	103 (32.8)	0.549	0.038
anticoagulation(%)	6063 (56.0)	46 (14.6)	<0.001	0.961
NSAIDs(%)	783 (7.2)	40 (12.7)	<0.001	0.184
PPI(%)	6582 (60.8)	150 (47.8)	<0.001	0.265
statins(%)	5930 (54.8)	180 (57.3)	0.410	0.051
ARB(%)	3011 (27.8)	94 (29.9)	0.450	0.046
β-blocker(%)	6883 (63.6)	162 (51.6)	<0.001	0.245
CCB(%)	3053 (28.2)	62 (19.7)	0.001	0.200
Digoxin(%)	1644 (15.2)	81 (25.8)	<0.001	0.265
Has-Bled,median[IQR]	1 [1, 2]	2 [1, 2]	<0.001	0.317
CHA2DS2-VASC,median[IQR]	3 [1, 4]	4 [3, 5]	<0.001	0.792

transaminase, AST: Aspartate transaminase , ALP: Alkaline phosphatase, PLT: Platelet count, Hb: Hemoglobin, NSAIDs: Nonsteroidal antiinflammatory drugs, PPI: Proton pump inhibitor, ARB: Angiotensin receptor blockers, CCB: Calcium entry blockers

**Supplementary Table 3. Event Counts by Treatment and Outcome for Patients with AF and AF with COPD**

Outcomes	AF-only(N=10818) <sup>a</sup>		AF+COPD(N=314) <sup>b</sup>	
	Warfarin (N=1189)	DOACs <sup>c</sup> (N=9629)	Warfarin (N=43)	DOACs (N=271)
Total Bleeding	85(7.15)	893(9.27)	6(13.95)	21(7.75)
Major Bleeding	18(1.51)	262(2.72)	1(2.33)	9 (3.32)
Minor Bleeding	69(5.80)	631(6.55)	5(11.63)	12(4.43)
All-cause death	128(10.77)	629(6.53)	6(13.95)	33(12.18)
thromboembolic events <sup>d</sup>	28(2.35)	246(2.55)	0(0)	7(2.58)
NACE <sup>e</sup>	44(3.70)	408(4.24)	1(2.33)	16(5.90)

Footnotes: Values are n (%), where % is the column percentage within each treatment group. Counts shown here are unweighted; overlap-weighted effective counts and absolute risks are provided in Supplementary table.

a. AF-only denotes atrial fibrillation without COPD.

b. AF-only denotes atrial fibrillation without COPD.

c. DOACs include dabigatran, apixaban, rivaroxaban, and edoxaban.

d. thromboembolic events indicates thromboembolism (ischemic stroke or systemic embolism).

e. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).

**Supplementary Table 4. Overlap-weighted event counts and absolute risks by treatment arm, shown separately for AF-only and AF+COPD<sup>a</sup>**

Outcomes	OACs	AF-only			AF+COPD		
		Non-events	Events	Rate(%) <sup>b</sup>	Non-events	Events	Rate(%)
Total bleeding	Warfarin	10446.09	685.91	6.16	9438.34	1693.66	15.21
	DOAC	10170.67	961.33	8.64	10230.51	901.49	8.10
Major bleeding	Warfarin	10894.18	237.82	2.14	10694.27	437.73	3.93
	DOAC	10703.70	428.30	3.85	10745.68	386.32	3.47
Minor bleeding	Warfarin	10653.58	478.42	4.30	9703.47	1428.53	12.83
	DOAC	10598.10	533.90	4.80	10598.52	533.48	4.79
All cause death	Warfarin	9453.89	1678.11	15.07	9425.53	1706.47	15.33
	DOAC	9951.82	1180.18	10.60	9822.35	1309.65	11.76
NACE <sup>c</sup>	Warfarin	10764.26	367.74	3.30	10693.64	438.36	3.94
	DOAC	10500.55	631.45	5.67	10441.40	690.60	6.20

Footnotes:

a. Non-events and Events are weighted effective counts.

b. Rate (%):  $100 \times (\text{events}) / [(\text{events}) + (\text{non-events})]$  within each treatment arm.

c. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).

**Supplementary Table 5. Baseline characteristics in the matched cohort vs the excluded patients (PSM 1:1)**

Characteristic	Included(N=624)	Excluded(N=10508)	p	SMD
sex,male(%)	467 (74.8)	6059 (57.7)	<0.001	0.369
age,median[IQR]	76.00 [70.00, 83.00]	67.00 [59.00, 74.00]	<0.001	0.893
BMI,median[IQR]	23.44 [21.40, 25.16]	24.22 [21.91, 26.37]	<0.001	0.217
smoking(%)	265 (42.5)	3963 (37.7)	0.020	0.097
drinking(%)	174 (27.9)	2556 (24.3)	0.050	0.081
hypertension(%)	362 (58.0)	7095 (67.5)	<0.001	0.198
diabetes(%)	157 (25.2)	2483 (23.6)	0.409	0.036
HF(%)	324 (51.9)	2554 (24.3)	<0.001	0.593
gout(%)	40 (6.4)	337 (3.2)	<0.001	0.150
stroke(%)	130 (20.8)	1578 (15.0)	<0.001	0.152
CHD(%)	293 (47.0)	2074 (19.7)	<0.001	0.603
TIA(%)	38 (6.1)	366 (3.5)	0.001	0.122
hepatic insufficiency(%)	16 (2.6)	320 (3.0)	0.574	0.029
renal insufficiency(%)	80 (12.8)	1000 (9.5)	0.008	0.105
TBil,median[IQR]	13.60 [9.40, 18.60]	15.50 [10.70, 17.90]	0.002	0.029
albumin,median[IQR]	37.75 [34.20, 40.30]	38.50 [36.50, 40.80]	<0.001	0.229
ALT,median[IQR]	19.00 [12.88, 29.40]	22.00 [14.20, 29.40]	<0.001	0.076
AST,median[IQR]	24.00 [18.00, 35.00]	28.00 [20.00, 40.10]	<0.001	0.056
ALP,median[IQR]	78.00 [63.00, 92.00]	82.00 [65.00, 89.00]	0.288	0.015
creatinine,median[IQR]	89.50 [73.00, 113.00]	85.00 [69.00, 94.00]	<0.001	0.291
PLT,median[IQR]	196.00 [158.00, 240.25]	199.20 [157.00, 226.00]	0.087	0.140
Hb,median[IQR]	129.00 [113.30, 141.00]	131.60 [122.60, 143.20]	<0.001	0.251
antiplateletv	221 (35.4)	3241 (30.8)	0.019	0.097
anticoagulation(%)	82 (13.1)	6027 (57.4)	<0.001	1.044
NSAIDs(%)	91 (14.6)	732 (7.0)	<0.001	0.248
PPI(%)	306 (49.0)	6426 (61.2)	<0.001	0.245
statins(%)	369 (59.1)	5741 (54.6)	0.031	0.091
ARB(%)	206 (33.0)	2899 (27.6)	0.004	0.118
β_blocker(%)	310 (49.7)	6735 (64.1)	<0.001	0.294
CCB(%)	123 (19.7)	2992 (28.5)	<0.001	0.206
Digoxin(%)	151 (24.2)	1574 (15.0)	<0.001	0.234
Has-Bled,median[IQR]	2.00 [1.00, 2.00]	1.00 [1.00, 2.00]	<0.001	0.364
CHA2DS2-VASC,median[IQR]	4.00 [3.00, 6.00]	3.00 [1.00, 4.00]	<0.001	0.784

Footnotes: Values are median (interquartile range) except as noted

COPD: Chronic obstructive pulmonary disease, BMI: Body mass index, HF: Heart failure, CHD: coronary heart disease, TIA: Transient ischemic attack, DOACs: Direct oral anticoagulants, TBil: total bilirubin, ALT: Alanine transaminase, AST: Aspartate transaminase, ALP: Alkaline phosphatase, PLT: Platelet count, Hb: Hemoglobin, NSAIDs: Nonsteroidal antiinflammatory drugs, PPI: Proton pump inhibitor, ARB: Angiotensin receptor blockers, CCB: Calcium entry blockers

**Supplementary Table 6. Crude (unadjusted) and propensity-score–matched (1:1) associations of COPD (vs no COPD) with outcomes in the overall atrial fibrillation cohort, stratified by anticoagulant type**

Footnotes:

Outcomes	OACs	Crude(unadjusted) <sup>a</sup>			PSM(1:1) <sup>b</sup>		
		OR(95%CI)	RD(95%CI), % <sup>c</sup>	P for interaction	aOR(95%CI)	RD(95%CI), %	P for interaction
Total bleeding	Warfarin	2.11(0.86-5.13)	7.8(-0.8 to 21.0)	0.065	6.18(0.97-39.23)	11.4(-1.0 to 23.8)	0.016
	DOACs	0.82(0.52-1.29)	-1.4(-4.2 to 2.2)				
Major bleeding	Warfarin	1.55(0.20-11.88)	2.2(-1.4 to 13.8)	0.832	NE <sup>d</sup>	4.0(0.4 to 15.9)	-
	DOACs	1.23(0.62-2.41)	0.7(-1.0 to 3.4)				
Minor bleeding	Warfarin	2.14(0.81-5.60)	6.9(-0.9 to 19.8)	0.042	5.02(0.82-30.84)	8.9(-2.6 to 20.7)	0.026
	DOACs	0.66(0.37-1.19)	-2.0(-4.0 to 1.0)				
All-cause death	Warfarin	1.34(0.56-3.25)	4.2(-4.4 to 17.3)	0.426	2.16(0.44-10.66)	6.3(-10.0 to 20.4)	0.494
	DOACs	1.98(1.37-2.88)	5.7(2.2 to 9.9)				
NACE <sup>e</sup>	Warfarin	0.62(0.08-4.61)	0.1(-3.8 to 11.4)	0.433	NE	3.6(0.4 to 14.0)	-
	DOACs	1.42(0.85-2.37)	1.8(-0.6 to 5.0)				

a. Crude (unadjusted): within-OAC logistic model with COPD as the only predictor; interaction P from an unadjusted model with COPD×OAC in the overall cohort.

b. PSM (1:1): propensity scores using covariates with |SMD|>0.10; 1:1 nearest-neighbour matching.

c. RD(95%CI), %: absolute risk difference (COPD – no COPD), in percentage points.

d. NE: not estimable due to zero/sparse events or separation.

e. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).

**Supplementary Table 7. Overlap-weighted event counts and absolute risks by treatment group in patients with AF and COPD<sup>a</sup>**

Outcome	Warfarin			DOACs			Min weighted cell <sup>c</sup>
	Non-events	Events	Rate(%) <sup>b</sup>	Non-events	Events	Rate(%)	
Total bleeding	21.79	3.86	15.1	23.83	1.71	6.7	1.71
Major bleeding	25.61	0.04	0.2	25.22	0.32	1.3	0.04
Minor bleeding	21.82	3.83	14.9	24.15	1.39	5.4	1.39
All-cause death	23.39	2.26	8.8	23.05	2.49	9.8	2.26
NACE <sup>d</sup>	25.61	0.04	0.2	24.86	0.67	2.6	0.04

Footnotes:

- a. Weighted counts (non-events and events) are effective counts after applying overlap weights (ATO target population) and can be non-integers due to weighting; minor discrepancies may occur because of rounding.
- b. Rate (%):  $100 \times (\text{events}) / [(\text{events}) + (\text{non-events})]$  within each treatment arm.
- c. Min weighted cell: The minimum of the four overlap-weighted cells in the 2x2 table for that outcome (Warfarin-event, Warfarin-non-event, DOAC-event, DOAC-non-event); used as a small-cell diagnostic.
- d. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).

**Supplementary Table8. Sensitivity Analysis of DOAC vs Warfarin in Patients with AF-COPD: Odds Ratios (OR) and Risk Differences (RD)**

	Model 3 <sup>a</sup>		Model 4 <sup>b</sup>		Model 5 <sup>c</sup>	
	OR(95%CI)	RD(95%CI) <sup>d</sup>	aOR(95%CI)	RD(95%CI)	aOR(95%CI)	RD(95%CI)
Total bleeding	0.27(0.08 -0.96)	-6.2(-17.1 to 4.6)	0.21(0.07 -0.61)	-20.4(-44.9 to 4.1)	NE <sup>e</sup>	-17.0(-35.5 to 1.5)
Major bleeding	2.61(0.27 -25.09)	1.0(-4.0 to 6.0)	5.05(0.18 -140.66)	2.4(0.1 to 4.7)	99.652(0.46 -21499.61) <sup>f</sup>	0.5(-0.3 to 1.3)
Minor bleeding	0.18(0.04 -0.85)	-7.2(-17.1 to 2.7)	0.09(0.02 -0.40)	-22.8(-47.3 to 1.7)	NE	-17.5(-36.0 to 1.0)
All-cause death	1.01(0.33 -3.12)	-1.8(-12.9 to 9.3)	2.15(0.58 -7.91)	6.2(-0.3 to 12.8)	0.14(0 -3.79)	2.4(-17.5 to 22.4)
NACE <sup>g</sup>	0.78(0.11 -5.80)	3.6(-1.7 to 8.9)	7.16(0.30 -173.35)	4.8(1.9 to 7.7)	NE	0.7(-0.2 to 1.7)

Footnotes:

- a. Model 3 (Unweighted, adjusted): Logistic regression adjusted for prespecified clinical covariates and variables with residual imbalance ( $|SMD| > 0.10$ ). Adjusted covariates: albumin, BMI, CHA2DS2-VASC, creatinine, Has-Bled, PLT,  $\beta$ -blocker, antiplatelet, NSAIDs, PPI, Hb, TBil, ALT, AST, ALP, statins, ARB, CCB, Digoxin, smoking, drinking, hepatic-insufficiency, renal-insufficiency.
- b. Model 4 (IPTW, adjusted): Stabilized inverse probability of treatment weighting (ATE), probit propensity score, 1% tail trimming, Logistic regression adjusted for prespecified clinical covariates and variables with residual imbalance ( $|SMD| > 0.10$ ). Adjusted covariates: age, albumin, BMI, Has-Bled, PLT,  $\beta$ -blocker, CHD, HF
- c. Model 5 (Overlap weighting, antiplatelet excluded): Overlap weights from a probit propensity score after excluding patients receiving antiplatelet agents; covariates selected as above. Adjusted covariates: albumin, BMI, CHA2DS2-VASC.
- d. RD (95% CI): RD is expressed as absolute risk difference (%) without the percentage symbol, defined as DOAC – warfarin (attributable risk in DOAC minus attributable risk in warfarin), negative values favor DOAC.
- e. NE: not estimable due to sparse data (quasi-complete separation): in these instances, one treatment arm had near-zero weighted events, leading the logistic coefficient to diverge.
- f. The extremely large OR reflects sparse-data/(quasi-)complete separation after overlap weighting (with antiplatelet exclusion): the (weighted) event count in one arm was ~0, with very small effective sample size (ESS) and minimum weighted cell <5, causing the logit coefficient to diverge and the OR/CI to inflate.

e. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).

**Supplementary Table 9. Overlap-weighted event counts and absolute risks by renal function: eGFR  $\geq$ 60 vs <60 mL/min/1.73 m<sup>2</sup>, comparing warfarin with DOACs<sup>a</sup>**

Footnotes:

Outcomes	eGFR	Warfarin			DOACs		
		Non-events	Events	Rate(%) <sup>b</sup>	Non-events	Events	Rate(%)
Total bleeding	$\geq$ 60	16.72	3.07	0.16	16.71	1.36	0.08
	<60	5.66	1.05	0.16	7.92	0.58	0.07
Major bleeding	$\geq$ 60	19.79	0	0	17.79	0.27	0.02
	<60	6.61	0.11	0.02	8.37	0.13	0.02
Minor bleeding	$\geq$ 60	16.72	3.07	0.16	16.98	1.08	0.06
	<60	5.77	0.94	0.14	8.05	0.45	0.05
All cause death	$\geq$ 60	19.15	0.64	0.03	15.69	2.37	0.13
	<60	4.89	1.82	0.27	8.24	0.26	0.03
NACE <sup>c</sup>	$\geq$ 60	19.79	0	0	17.61	0.45	0.02
	<60	6.61	0.11	0.02	8.37	0.13	0.02

a. Weighted counts (non-events and events) are effective counts after applying overlap weights (ATO target population) and can be non-integers due to weighting.

b. Rate (%):  $100 \times (\text{events}) / [(\text{events}) + (\text{non-events})]$  within each treatment arm.

c. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).

**Supplementary Table 10. Overlap-weighted event counts and absolute risks by DOAC class (Factor Xa inhibitors vs dabigatran)<sup>a</sup>**

Outcomes	FXa inhibitors <sup>b</sup>			Dabigatran		
	Non-events	Events	Rate(%) <sup>c</sup>	Non-events	Events	Rate(%)
Total bleeding	13.64	2.27	14.28	14.87	0.89	5.64
Major bleeding	14.28	1.63	10.26	15.75	0.01	0.09
Minor bleeding	15.27	0.64	4.02	14.89	0.87	5.55
All-cause death	13.39	2.52	15.84	13.89	1.88	11.91
NACE <sup>d</sup>	13.80	2.11	13.28	14.21	1.56	9.88


Footnotes:

a. Weighted counts (non-events and events) are effective counts after applying overlap weights (ATO target population) and can be non-integers due to weighting


b. FXa inhibitors include apixaban, rivaroxaban, and edoxaban.

c. Rate (%):  $100 \times (\text{events}) / [(\text{events}) + (\text{non-events})]$  within each treatment arm.

d. NACE (net adverse clinical events) : thromboembolic events or major bleeding (composite).



Supplementary figure S1. Supplementary Figure S1. Covariate balance (|SMD|) across analytic methods—Unweighted vs Overlap weighting (ATO) vs 1:1 Propensity Score Matching.



Supplementary Figure S2. Covariate balance ( $|SMD|$ ) across methods—Unweighted vs IPTW (ATE) vs Overlap weighting (ATO), with and without antiplatelet-user exclusion.